...
首页> 外文期刊>Modern Pathology >Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma
【24h】

Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma

机译:在结肠腺癌中表达的新型免疫组化标记物在区分原发性卵巢癌和转移性大肠癌中的应用

获取原文
           

摘要

Distinguishing primary ovarian carcinoma, particularly endometrioid and mucinous subtypes, from metastatic colorectal carcinoma to the ovary is often difficult on histologic examination alone. Recently, three immunohistochemical markers CDX2, a homeobox gene encoding an intestine-specific transcription factor; -methylacyl-CoA racemase (AMACR/P504S), a mitochondrial and peroxisomal enzyme with fairly restricted expression in selective tumors and -catenin, an adenomatous polyposis coli (APC) mutation product resulting in activation of the Wnt pathway, have been reported to have specific and sensitive expression in colorectal carcinomas. We evaluated a panel consisting of antibodies to CDX2, -catenin and P504S in 23 primary ovarian adenocarcinomas (13 mucinous and 10 endometrioid) and compared the findings to 22 metastatic colorectal adenocarcinomas (seven mucinous and 15 nonmucinous tumors with endometrioid-like morphology hereafter referred to as pseudo-endometrioid) to the ovary stained with the same panel. Twenty (91%) metastatic tumors expressed at least two markers and seven (32%) expressed all three. In contrast, only three (13%) primary ovarian tumors expressed at least two markers and none expressed all three. Strong (2+, 3+) and diffuse (>40%) expression for CDX2 was noted in 21 (95%) metastatic tumors and five (22%) primary ovarian tumors (three mucinous, two endometrioid). P504S was similarly expressed in seven (32%) metastatic and none of the primary ovarian carcinomas. Nuclear expression of -catenin was noted in 13 (59%) metastatic tumors and in eight cases (36%), it was diffuse and strong. In contrast, four (19%) primary tumors showed nuclear expression of this protein with only one (5%) case expressing it in a diffuse pattern. Immunohistochemical expression of gene products and enzymes of colorectal carcinogenesis in some primary ovarian carcinomas suggest that the morphologic similarities between colorectal and mucinous/endometrioid carcinoma of the ovary extends to the genetic level, although differences in the level of expression exist between these tumors. Diffuse expression of all three markers (CDX2, -catenin and P504S) in a tumor in the ovary was found to be virtually diagnostic of metastasis from a colorectal primary in this study.
机译:仅从组织学检查上就很难区分原发性卵巢癌,特别是子宫内膜样和粘液性亚型,从转移性结直肠癌到卵巢。最近,三个免疫组织化学标记CDX2是一个编码肠特异性转录因子的同源盒基因。据报道,在选择性肿瘤中表达受到相当限制的线粒体和过氧化物酶体酶-甲基酰基辅酶A消旋酶(AMACR / P504S)和导致Wnt途径活化的腺瘤性息肉病大肠杆菌(APC)突变产物-catenin具有特异性在大肠癌中的表达和敏感性我们评估了一组由CDX2,-catenin和P504S抗体组成的小组,涉及23例原发性卵巢腺癌(13粘液性和10子宫内膜样癌),并将研究结果与22转移性结直肠腺癌(7粘液性和15非粘液性肿瘤,具有子宫内膜样样形态)如假子宫内膜样异位)到相同的面板染色的卵巢。二十个(91%)转移性肿瘤表达了至少两个标记,七个(32%)表达了所有三个标记。相比之下,只有三个(13%)的原发性卵巢肿瘤表达了至少两个标记,而没有一个表达所有三个标记。在21例(95%)转移性肿瘤和5例(22%)的原发性卵巢肿瘤(3例粘液,2例子宫内膜异位)中发现了CDX2的强(2 +,3 +)和弥漫性(> 40%)表达。 P504S在7例(32%)转移性癌中类似表达,但均未表达。在13例(59%)的转移性肿瘤中发现了-catenin的核表达,而在8例(36%)的转移性肿瘤中则可见-catenin的核表达。相比之下,有四个(19%)原发性肿瘤显示了该蛋白的核表达,只有一个(5%%)病例以扩散模式表达该蛋白。在一些原发性卵巢癌中,基因产物和结直肠癌发生酶的免疫组织化学表达表明,尽管这些肿瘤之间表达水平存在差异,但结直肠癌与粘液性/子宫内膜样癌之间的形态相似性已扩展到遗传水平。在这项研究中,发现卵巢肿瘤中所有三种标记物(CDX2,-catenin和P504S)的弥漫性表达实际上可以诊断结直肠癌的转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号